662 related articles for article (PubMed ID: 27818234)
1. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
2. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).
Quaranta MG; Cavalletto L; Russo FP; Calvaruso V; Ferrigno L; Zanetto A; Mattioli B; D'Ambrosio R; Panetta V; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Rosselli Del Turco E; Massari M; Licata A; Barbaro F; Persico M; Morisco F; Pompili M; Cerini F; Puoti M; Santantonio T; Craxì A; Kondili LA; Chemello L; On Behalf Of Piter Collaborating Investigators
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793565
[TBL] [Abstract][Full Text] [Related]
3. Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis.
John BV; Dang Y; Kaplan DE; Jou JH; Taddei TH; Spector SA; Martin P; Bastaich DR; Chao HH; Dahman B
Clin Gastroenterol Hepatol; 2024 Apr; 22(4):778-788.e7. PubMed ID: 38061410
[TBL] [Abstract][Full Text] [Related]
4. Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
Toyoda H; Tada T; Uojima H; Nozaki A; Chuma M; Takaguchi K; Hiraoka A; Abe H; Itobayashi E; Matsuura K; Atsukawa M; Watanabe T; Shimada N; Nakamuta M; Kojima M; Tsuji K; Mikami S; Ishikawa T; Yasuda S; Tsutsui A; Arai T; Kumada T; Tanaka Y; Tanaka J; Chayama K
J Gastroenterol Hepatol; 2024 May; 39(5):949-954. PubMed ID: 38291715
[TBL] [Abstract][Full Text] [Related]
5. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.
Kobayashi S; Takeda T; Enomoto M; Tamori A; Kawada N; Habu D; Sakaguchi H; Kuroda T; Kioka K; Kim SR; Kanno T; Ueda T; Hirano M; Fujimoto S; Jomura H; Nishiguchi S; Seki S
Liver Int; 2007 Mar; 27(2):186-91. PubMed ID: 17311612
[TBL] [Abstract][Full Text] [Related]
6. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
[TBL] [Abstract][Full Text] [Related]
7. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
8. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study.
Ikeda K; Saitoh S; Kobayashi M; Suzuki Y; Suzuki F; Tsubota A; Arase Y; Murashima N; Chayama K; Kumada H
J Gastroenterol Hepatol; 2001 Apr; 16(4):406-15. PubMed ID: 11354279
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
Hung CH; Lee CM; Lu SN; Wang JH; Hu TH; Tung HD; Chen CH; Chen WJ; Changchien CS
J Viral Hepat; 2006 Jun; 13(6):409-14. PubMed ID: 16842444
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy.
D'Ambrosio R; Della Corte C; Colombo M
Int J Mol Sci; 2015 Aug; 16(8):19698-712. PubMed ID: 26295392
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
[TBL] [Abstract][Full Text] [Related]
13. Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
Hino K; Kitase A; Satoh Y; Fujiwara D; Yamaguchi Y; Korenaga M; Shingai Y; Konishi T; Yamashita S; Uchida K; Mori K; Hanada H; Kodama T; Nukui K; Okita K
J Viral Hepat; 2002 Sep; 9(5):370-6. PubMed ID: 12225332
[TBL] [Abstract][Full Text] [Related]
14. Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response.
Chida T; Ohta K; Noritake H; Matsushita M; Murohisa G; Kageyama F; Sasada Y; Oyaizu T; Tsugiki M; Tamakoshi K; Nakajima T; Suda T; Kawata K
Sci Rep; 2024 May; 14(1):10864. PubMed ID: 38740815
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment.
Chavalitdhamrong D; Tanwandee T
World J Gastroenterol; 2006 Sep; 12(34):5532-5. PubMed ID: 17006994
[TBL] [Abstract][Full Text] [Related]
16. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M
Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733
[TBL] [Abstract][Full Text] [Related]
17. The impact of antiviral therapy on the course of chronic HCV infection. A systematic review.
Almasio PL; Venezia G; Craxì A
Panminerva Med; 2003 Sep; 45(3):175-82. PubMed ID: 14618115
[TBL] [Abstract][Full Text] [Related]
18. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.
Celli R; Saffo S; Kamili S; Wiese N; Hayden T; Taddei T; Jain D
Arch Pathol Lab Med; 2021 Apr; 145(4):419-427. PubMed ID: 32810870
[TBL] [Abstract][Full Text] [Related]
19. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.
Yoshida H; Tateishi R; Arakawa Y; Sata M; Fujiyama S; Nishiguchi S; Ishibashi H; Yamada G; Yokosuka O; Shiratori Y; Omata M
Gut; 2004 Mar; 53(3):425-30. PubMed ID: 14960528
[TBL] [Abstract][Full Text] [Related]
20. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.
Omata M; Yoshida H; Shiratori Y
Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S141-3. PubMed ID: 16234063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
